Skip to main content
SMFM 2024 Pregnancy Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared on social media
Faculty have requested this content not be shared on social media
CME Credit Offered
CME Credit Offered
Poster Icons
Foundation Awardee
Foundation Awardee
No Social Media
No Social Media
Back
Q&A

Epidemiology

Poster Session 3

(739) Maternal fertility treatments and the risk for celiac disease of the offspring

Wednesday, February 14, 2024
8:30 AM – 10:00 AM  
Location: Prince George's Exhibit Hall CDE, Lower Atrium Level

    Primary & Presenting Author(s)

  • Gil Gutvirtz, MD

    Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
    Metar, HaDarom, Israel

    • Coauthor(s)

  • Gali Pariente, MD

    Acting director of Fetal Maternal Unit B Division of Obstetrics and Gynecology
    Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel
    Klahim, HaDarom, Israel

  • Tamar Wainstock, PhD (she/her/hers)

    Ben Gurion University
    Beer-Sheva, HaDarom, Israel

  • Eyal Sheiner, MD, PhD

    Head of department of Obstetrics and Gynecology B, Soroka University Medical Center
    Soroka University Medical Center
    Beer-Sheva, HaDarom, Israel

Objective: Fertility treatments affect the female hormonal and immunological milieu, which also support the growing fetus. As celiac disease is known to be an immune-mediated disorder, we opted to investigate whether offspring of women conceived using fertility treatments are at higher risk to develop celiac disease.

Study Design: A large population-based cohort study including all singleton deliveries in a tertiary medical center between the years 1991 and 2021 was conducted. The risk for celiac disease was compared between children (up to the age of 18 years) of women who conceived using fertility treatments (including ovulation induction with or without intrauterine insemination and in-vitro fertilization) and children born after spontaneously conceived pregnancies. Data for celiac disease diagnosis were extracted from community-based clinics and hospitalization records. Kaplan-Meier survival curve was used to compare the incidence of celiac disease between the study groups. A Cox proportional hazards model was used to control for possible confounders.

Results: A total of 356,356 singleton deliveries were included in the study, of which 7,711 (2.2%) deliveries were pregnancies conceived using fertility treatments. Children born following fertility treatments had comparable rate of celiac disease as children who were born following spontaneously conceived pregnancies (0.6% vs. 0.5%, p=0.477, Figure). The Kaplan-Meier survival curve illustrated comparable cumulative incidence of celiac disease in both groups (Log Rank, p=0.285, Figure). Using a Cox proportional hazards model, controlling for maternal age and gestational age, fertility treatments were not associated with celiac disease of the offspring (adjusted hazard ratio (HR)=1.13, 95%CI 0.84-1.52, p=0.392, Figure).

Conclusion: Fertility treatments do not increase the risk for celiac disease of the offspring.